A new broom sweeps clean: CLDN16 surpasses the BRAF-V600E mutation as an unrivaled biomarker in papillary thyroid cancer
Authors' conclusion
CLDN16 presents a promising biomarker that could surpass BRAF-V600E, offering effective clinical utility and revolutionizing PTC molecular typing for precise high-risk identification.
Study context
- Population
- Papillary thyroid cancer (PTC) and normal thyroid/para-tumor tissues; TCGA and single-centre cohorts
- Comparison
- CLDN16 vs BRAF-V600E as PTC biomarker
- Outcome
- Positive detection rate and diagnostic accuracy for PTC
Methodological detailsdatabase analyses, tissue validation, RNA sequencing, functional assays, support vector machine model
- Database analyses
- Tissue validation
- RNA sequencing
- Functional assays
- Support vector machine model
Performance
As reported in the abstract
Positive detection rate, TCGA
Positive detection rate, our center
| Outcome | CLDN16 | BRAF-V600E |
|---|---|---|
| ROC (TCGA) | 0.922 | 0.742 |
Further findings
CLDN16 expression across sites and aggressive features
- Stable expression across primary and metastatic sites
- Associated with extrathyroidal extension and lymph node metastasis
- Knockdown inhibited migration, invasion and iodine uptake in PTC cells
Malignancy identification in BRAF wild patients
- CLDN16 in BRAF wild patients
- 94.2%
- CLDN16 combined with BRAF-V600E, accuracy
- 96.9%
High-risk identification with CLDN16-incorporated molecular typing
- Accuracy, training set
- 92.0%
- Accuracy, validation set
- 100%
Original publication
A new broom sweeps clean: CLDN16 surpasses the BRAF-V600E mutation as an unrivaled biomarker in papillary thyroid cancer. Eur J Endocrinol. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →